

Literaturverzeichnis

- [1] World Health Organization, *WHO global report on traditional and complementary medicine 2019*. Geneva: World Health Organization, 2019. Zugriff am: 30.12.2024. [Online]. <https://iris.who.int/handle/10665/312342>
- [2] P. J. Houghton, 'The Role of Plants in Traditional Medicine and Current Therapy', *The Journal of Alternative and Complementary Medicine*, vol. 1, no. 2, pp. 131–143, Jun. 1995, doi: 10.1089/acm.1995.1.131.
- [3] F.-S. Li and J.-K. Weng, 'Demystifying traditional herbal medicine with modern approach', *Nature Plants*, vol. 3, no. 8, p. 17109, Jul. 2017, doi: 10.1038/nplants.2017.109.
- [4] N. Galeotti, 'Hypericum perforatum (St John's wort) beyond depression: A therapeutic perspective for pain conditions', *Journal of Ethnopharmacology*, vol. 200, pp. 136–146, Mar. 2017, doi: 10.1016/j.jep.2017.02.016.
- [5] K. Linde, M. Berner, M. Egger, and C. Mulrow, 'St John's wort for depression: Meta-analysis of randomised controlled trials', *Br J Psychiatry*, vol. 186, no. 2, pp. 99–107, Feb. 2005, doi: 10.1192/bjp.186.2.99.
- [6] Q. X. Ng, N. Venkatanarayanan, and C. Y. X. Ho, 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', *Journal of Affective Disorders*, vol. 210, pp. 211–221, Mar. 2017, doi: 10.1016/j.jad.2016.12.048.
- [7] M. Härter, C. Klesse, I. Bermejo, F. Schneider, and M. Berger, 'Unipolar Depression', *Deutsches Ärzteblatt international*, Oct. 2010, doi: 10.3238/arztebl.2010.0700.
- [8] Europäisches Parlament und Rat der Europäischen Union, 'Richtlinie 2001/83/EG des Europäischen Parlaments und des Rates vom 6. November 2001 über ein Gemeinschaftskodex für Humanarzneimittel'. Zugriff am: 05.01.2025. [Online]. <https://eur-lex.europa.eu/legal-content/DE/TXT/?uri=celex%3A32001L0083>
- [9] European Medicines Agency (EMA), 'Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials (Revision 2)', Committee for Medicinal Products for Human Use (CHMP), Amsterdam, Netherlands (EMA-Sitz), Guideline / Scientific Guideline EMA/CHMP/BWP/534898/2008 Rev. 2, Jun. 2018.
- [10] J. H. Kim and A. R. Scialli, 'Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease', *Toxicological Sciences*, vol. 122, no. 1, pp. 1–6, Jul. 2011, doi: 10.1093/toxsci/kfr088.
- [11] M. Martens and N. Carbonnelle, 'THE EU REGULATORY FRAMEWORK FOR MEDICINAL PRODUCTS FOR HUMAN USE', in *EU Law of Competition and Trade in the Pharmaceutical Sector*, P. Figueroa and A. Guerrero, Eds., Edward Elgar Publishing, 2019, pp. 503–551. doi: 10.4337/9781785362613.00022.
- [12] P. S., 'Toxicological screening', *Journal of Pharmacology and Pharmacotherapeutics*, vol. 2, no. 2, pp. 74–79, Jun. 2011, doi: 10.4103/0976-500X.81895.
- [13] J. Wang *et al.*, 'Target identification of natural and traditional medicines with quantitative chemical proteomics approaches', *Pharmacology & Therapeutics*, vol. 162, pp. 10–22, Jun. 2016, doi: 10.1016/j.pharmthera.2016.01.010.
- [14] X. Chen *et al.*, 'Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification', *Sig Transduct Target Ther*, vol. 5, no. 1, p. 72, May 2020, doi: 10.1038/s41392-020-0186-y.
- [15] F. Olivon *et al.*, 'Bioactive Natural Products Prioritization Using Massive Multi-informational Molecular Networks', *ACS Chem. Biol.*, vol. 12, no. 10, pp. 2644–2651, Oct. 2017, doi: 10.1021/acscchembio.7b00413.
- [16] L.-F. Nothias *et al.*, 'Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural Product Bioassay-Guided Fractionation', *J. Nat. Prod.*, vol. 81, no. 4, pp. 758–767, Apr. 2018, doi: 10.1021/acs.jnatprod.7b00737.
- [17] S. K. Ahmed *et al.*, 'Antimicrobial resistance: Impacts, challenges, and future prospects', *Journal of Medicine, Surgery, and Public Health*, vol. 2, p. 100081, Apr. 2024, doi: 10.1016/j.glmedi.2024.100081.
- [18] Z. D. Pana and T. Zaoutis, 'Treatment of extended-spectrum β -lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?', *F1000Res*, vol. 7, p. F1000 Faculty Rev-1347, 2018, doi: 10.12688/f1000research.14822.1.

- [19] K. Schaufler *et al.*, ‘Carriage of Extended-Spectrum Beta-Lactamase-Plasmids Does Not Reduce Fitness but Enhances Virulence in Some Strains of Pandemic *E. coli* Lineages’, *Front. Microbiol.*, vol. 7, Mar. 2016, doi: 10.3389/fmicb.2016.00336.
- [20] A. Casadevall and L. Pirofski, ‘Host-Pathogen Interactions: Redefining the Basic Concepts of Virulence and Pathogenicity’, *Infect Immun*, vol. 67, no. 8, pp. 3703–3713, Aug. 1999, doi: 10.1128/IAI.67.8.3703-3713.1999.
- [21] S. Baron, Ed., *Medical Microbiology*, 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston, 1996. Zugriff am: 05.01.2025. [Online]. <http://www.ncbi.nlm.nih.gov/books/NBK7627/>
- [22] H.-J. Wu, A. H.-J. Wang, and M. P. Jennings, ‘Discovery of virulence factors of pathogenic bacteria’, *Current Opinion in Chemical Biology*, vol. 12, no. 1, pp. 93–101, Feb. 2008, doi: 10.1016/j.cbpa.2008.01.023.
- [23] H.-C. Flemming, J. Wingender, U. Szewzyk, P. Steinberg, S. A. Rice, and S. Kjelleberg, ‘Biofilms: an emergent form of bacterial life’, *Nat Rev Microbiol*, vol. 14, no. 9, pp. 563–575, Sep. 2016, doi: 10.1038/nrmicro.2016.94.
- [24] L. Emdy, ‘Virulence factors of uropathogenic *Escherichia coli*’, *International Journal of Antimicrobial Agents*, vol. 22, pp. 29–33, Oct. 2003, doi: 10.1016/S0924-8579(03)00236-X.
- [25] I. J. Schalk, ‘Bacterial siderophores: diversity, uptake pathways and applications’, *Nat Rev Microbiol*, vol. 23, no. 1, pp. 24–40, Jan. 2025, doi: 10.1038/s41579-024-01090-6.
- [26] B. R. Wilson, A. R. Bogdan, M. Miyazawa, K. Hashimoto, and Y. Tsuji, ‘Siderophores in Iron Metabolism: From Mechanism to Therapy Potential’, *Trends Mol Med*, vol. 22, no. 12, pp. 1077–1090, Dec. 2016, doi: 10.1016/j.molmed.2016.10.005.
- [27] F. B. M. Lara *et al.*, ‘Virulence Markers and Phylogenetic Analysis of *Escherichia coli* Strains with Hybrid EAEC/UPEC Genotypes Recovered from Sporadic Cases of Extraintestinal Infections’, *Front. Microbiol.*, vol. 8, Feb. 2017, doi: 10.3389/fmicb.2017.00146.
- [28] J. B. Kaper, J. P. Nataro, and H. L. T. Mobley, ‘Pathogenic *Escherichia coli*’, *Nat Rev Microbiol*, vol. 2, no. 2, pp. 123–140, Feb. 2004, doi: 10.1038/nrmicro818.
- [29] J. Geurtsen, M. de Been, E. Weerdenburg, A. Zomer, A. McNally, and J. Poolman, ‘Genomics and pathotypes of the many faces of *Escherichia coli*’, *FEMS Microbiology Reviews*, vol. 46, no. 6, p. fuac031, Nov. 2022, doi: 10.1093/femsre/fuac031.
- [30] O. Clermont, J. K. Christenson, E. Denamur, and D. M. Gordon, ‘The Clermont *Escherichia coli* phylo-typing method revisited: improvement of specificity and detection of new phylogroups’, *Environ Microbiol Rep*, vol. 5, no. 1, pp. 58–65, Feb. 2013, doi: 10.1111/1758-2229.12019.
- [31] A. Montes-Robledo, Y. Buelvas-Montes, and R. Baldiris-Avila, ‘Description of extraintestinal pathogenic *Escherichia coli* based on phylogenetic grouping, virulence factors, and antimicrobial susceptibility’, *IJM*, Sep. 2023, doi: 10.18502/ijm.v15i4.13504.
- [32] C. Ewers *et al.*, ‘CTX-M-15-D-ST648 *Escherichia coli* from companion animals and horses: another pandemic clone combining multiresistance and extraintestinal virulence?’, *Journal of Antimicrobial Chemotherapy*, vol. 69, no. 5, pp. 1224–1230, May 2014, doi: 10.1093/jac/dkt516.
- [33] T. J. Finn *et al.*, ‘A Comprehensive Account of *Escherichia coli* Sequence Type 131 in Wastewater Reveals an Abundance of Fluoroquinolone-Resistant Clade A Strains’, *Appl Environ Microbiol*, vol. 86, no. 4, pp. e01913-19, Feb. 2020, doi: 10.1128/AEM.01913-19.
- [34] S. Topçu and M. G. Şeker, ‘In Vitro Antimicrobial Effects and Inactivation Mechanisms of 5,8-Dihydroxy-1,4-Naphthoquinone’, *Antibiotics (Basel)*, vol. 11, no. 11, p. 1537, Nov. 2022, doi: 10.3390/antibiotics11111537.
- [35] K. Schaufler *et al.*, ‘Genomic and Functional Analysis of Emerging Virulent and Multidrug-Resistant *Escherichia coli* Lineage Sequence Type 648’, *Antimicrob Agents Chemother*, vol. 63, no. 6, pp. e00243-19, Jun. 2019, doi: 10.1128/AAC.00243-19.
- [36] D. Sharma, L. Misba, and A. U. Khan, ‘Antibiotics versus biofilm: an emerging battleground in microbial communities’, *Antimicrob Resist Infect Control*, vol. 8, no. 1, p. 76, Dec. 2019, doi: 10.1186/s13756-019-0533-3.
- [37] S. Guenther *et al.*, ‘Detection of pandemic B2-O25-ST131 *Escherichia coli* harbouring the CTX-M-9 extended-spectrum -lactamase type in a feral urban brown rat (*Rattus norvegicus*)’, *Journal of Antimicrobial Chemotherapy*, vol. 65, no. 3, pp. 582–584, Mar. 2010, doi: 10.1093/jac/dkp496.

- [38] A. Ranjan *et al.*, 'ESBL-plasmid carriage in *E. coli* enhances in vitro bacterial competition fitness and serum resistance in some strains of pandemic sequence types without overall fitness cost', Jun. 15, 2018, *Robert Koch-Institut*. doi: 10.25646/5696.
- [39] C. Baron, 'Antivirulence drugs to target bacterial secretion systems', *Current Opinion in Microbiology*, vol. 13, no. 1, pp. 100–105, Feb. 2010, doi: 10.1016/j.mib.2009.12.003.
- [40] A. G. Atanasov *et al.*, 'Natural products in drug discovery: advances and opportunities', *Nat Rev Drug Discov*, vol. 20, no. 3, pp. 200–216, Mar. 2021, doi: 10.1038/s41573-020-00114-z.
- [41] R. A. Dixon and A. J. Dickinson, 'A century of studying plant secondary metabolism—From “what?” to “where, how, and why?”', *Plant Physiology*, vol. 195, no. 1, pp. 48–66, Apr. 2024, doi: 10.1093/plphys/kiad596.
- [42] P.-G. Pietta, 'Flavonoids as Antioxidants', *J. Nat. Prod.*, vol. 63, no. 7, pp. 1035–1042, Jul. 2000, doi: 10.1021/np9904509.
- [43] S. J. Maleki, J. F. Crespo, and B. Cabanillas, 'Anti-inflammatory effects of flavonoids', *Food Chemistry*, vol. 299, p. 125124, Nov. 2019, doi: 10.1016/j.foodchem.2019.125124.
- [44] A. Gomes, E. Fernandes, J. Lima, L. Mira, and M. Corvo, 'Molecular Mechanisms of Anti-Inflammatory Activity Mediated by Flavonoids', *CMC*, vol. 15, no. 16, pp. 1586–1605, Jul. 2008, doi: 10.2174/092986708784911579.
- [45] T. P. T. Cushnie and A. J. Lamb, 'Antimicrobial activity of flavonoids', *International Journal of Antimicrobial Agents*, vol. 26, no. 5, pp. 343–356, Nov. 2005, doi: 10.1016/j.ijantimicag.2005.09.002.
- [46] S. Manner, M. Skogman, D. Goeres, P. Vuorela, and A. Fallarero, 'Systematic Exploration of Natural and Synthetic Flavonoids for the Inhibition of *Staphylococcus aureus* Biofilms', *IJMS*, vol. 14, no. 10, pp. 19434–19451, Sep. 2013, doi: 10.3390/ijms141019434.
- [47] N. A. Al-Shabib, F. M. Husain, I. Ahmad, M. S. Khan, R. A. Khan, and J. M. Khan, 'Rutin inhibits mono and multi-species biofilm formation by foodborne drug resistant *Escherichia coli* and *Staphylococcus aureus*', *Food Control*, vol. 79, pp. 325–332, Sep. 2017, doi: 10.1016/j.foodcont.2017.03.004.
- [48] L. G. Sarbu, L. G. Bahrin, C. Babii, M. Stefan, and M. L. Birsa, 'Synthetic flavonoids with antimicrobial activity: a review', *J Appl Microbiol*, vol. 127, no. 5, pp. 1282–1290, Nov. 2019, doi: 10.1111/jam.14271.
- [49] M. F. G. Rocha *et al.*, 'Antifungal effects of the flavonoids kaempferol and quercetin: a possible alternative for the control of fungal biofilms', *Biofouling*, vol. 35, no. 3, pp. 320–328, Mar. 2019, doi: 10.1080/08927014.2019.1604948.
- [50] C. Majdi, V. Duvauchelle, P. Meffre, and Z. Benfodda, 'An overview on the antibacterial properties of juglone, naphthazarin, plumbagin and lawsone derivatives and their metal complexes', *Biomedicine & Pharmacotherapy*, vol. 162, p. 114690, Jun. 2023, doi: 10.1016/j.biopha.2023.114690.
- [51] E. S. Ahmadi *et al.*, 'Naphthoquinone Derivatives Isolated from Plants: Recent Advances in Biological Activity', *MRMC*, vol. 20, no. 19, pp. 2019–2035, Dec. 2020, doi: 10.2174/1389557520666200818212020.
- [52] R. C. Montenegro *et al.*, 'Cytotoxic activity of naphthoquinones with special emphasis on juglone and its 5-O-methyl derivative', *Chemico-Biological Interactions*, vol. 184, no. 3, pp. 439–448, Mar. 2010, doi: 10.1016/j.cbi.2010.01.041.
- [53] F. Rivadavia, K. Kondo, M. Kato, and M. Hasebe, 'Phylogeny of the sundews, *Drosera* (Droseraceae), based on chloroplast *rbc L* and nuclear 18S ribosomal DNA Sequences', *American J of Botany*, vol. 90, no. 1, pp. 123–130, Jan. 2003, doi: 10.3732/ajb.90.1.123.
- [54] S. Eschenbrenner, C. M. Müller, B. Gemeinholzer, and V. Wissemann, 'Genetic diversity and implications for conservation strategies of *Drosera rotundifolia* L. (Droseraceae) in northern Germany (Schleswig-Holstein)', *Mires and Peat*, no. 24, pp. 1–12, Oct. 2019, doi: 10.19189/MaP.2018.KHR.375.
- [55] M. F. Melzig, H. H. Pertz, and L. Krenn, 'Anti-inflammatory and spasmolytic activity of extracts from *Droserae Herba*', *Phytomedicine*, vol. 8, no. 3, pp. 225–229, Jan. 2001, doi: 10.1078/0944-7113-00031.
- [56] B. Baranyai and H. Joosten, 'Biology, ecology, use, conservation and cultivation of round-leaved sundew (*Drosera rotundifolia* L.): a review', *Mires and Peat*, no. 18, pp. 1–28, Sep. 2016, doi: 10.19189/MaP.2015.OMB.212.

- [57] C. Braunberger *et al.*, 'Flavonoids as chemotaxonomic markers in the genus *Drosera*', *Phytochemistry*, vol. 118, pp. 74–82, Oct. 2015, doi: 10.1016/j.phytochem.2015.08.017.
- [58] A. Culham and R. J. Gornall, 'The taxonomic significance of naphthoquinones in the Droseraceae', *Biochemical Systematics and Ecology*, vol. 22, no. 5, pp. 507–515, Jul. 1994, doi: 10.1016/0305-1978(94)90045-0.
- [59] L. Krenn, U. Blaeser, and N. Hausknost-Chenicsek, 'Determination of Naphthoquinones in *Droserae herba* by Reversed-Phase High Performance Liquid Chromatography', *Journal of Liquid Chromatography & Related Technologies*, vol. 21, no. 20, pp. 3149–3160, Dec. 1998, doi: 10.1080/10826079808001264.
- [60] B. Baranyai, C. Bäcker, and C. Reich, 'The production of 7-methyljuglone, plumbagin and quercetin in wild and cultivated *Drosera rotundifolia* and *Drosera intermedia*', *Mires and Peat*, no. 18, pp. 1–8, Sep. 2016, doi: 10.19189/MaP.2016.OMB.228.
- [61] G. Gaudig and F. Tanneberger, 'Peatland Science and Conservation: Contributions of the Greifswald Mire Centre, Germany', in *Current Trends in Landscape Research*, L. Mueller and F. Eulenstein, Eds., in *Innovations in Landscape Research*, Cham: Springer International Publishing, 2019, pp. 611–629. doi: 10.1007/978-3-030-30069-2_28.
- [62] D. Hering *et al.*, 'Securing success for the Nature Restoration Law', *Science*, vol. 382, no. 6676, pp. 1248–1250, Dec. 2023, doi: 10.1126/science.adk1658.
- [63] Bundesministerium für Ernährung und Landwirtschaft (BMEL), 'Nationale Moorschutzstrategie'. Zugriff am: 08.01.2025 [Online]. <https://www.bmuv.de/themen/naturschutz/moorschutz>
- [64] L. Krenn *et al.*, 'In vitro Antispasmodic and Antiinflammatory Effects of *Drosera rotundifolia*', *Arzneimittelforschung*, vol. 54, no. 07, pp. 402–405, Dec. 2011, doi: 10.1055/s-0031-1296991.
- [65] A. Hake, F. Begrow, V. Spiegler, N. Symma, A. Hensel, and M. Düfer, 'Effects of Extracts and Flavonoids from *Drosera rotundifolia* L. on Ciliary Beat Frequency and Murine Airway Smooth Muscle', *Molecules*, vol. 27, no. 19, p. 6622, Oct. 2022, doi: 10.3390/molecules27196622.
- [66] K. Fukushima *et al.*, '*Drosera rotundifolia* and *Drosera tokaiensis* suppress the activation of HMC-1 human mast cells', *Journal of Ethnopharmacology*, vol. 125, no. 1, pp. 90–96, Aug. 2009, doi: 10.1016/j.jep.2009.06.009.
- [67] 'AMIS-Datenbank (DIMDI)', AMIS-Datenbank (DIMDI). Zugriff am: 08.01.2025 [Online]. <https://portal.dimdi.de/amguifree/am/search.xhtml>
- [68] D. Pratiwi and T. W. Yuwati, 'Paludiculture: peatland utilization to support climate change adaptation', *IOP Conf. Ser.: Earth Environ. Sci.*, vol. 1109, no. 1, p. 012001, Nov. 2022, doi: 10.1088/1755-1315/1109/1/012001.
- [69] G. Calapai, 'European Legislation on Herbal Medicines: A Look into the Future', *Drug Safety*, vol. 31, no. 5, pp. 428–431, 2008, doi: 10.2165/00002018-200831050-00009.
- [70] European Directorate for the Quality of Medicines & HealthCare (EDQM), 'Guide for the elaboration of monographs on herbal drugs and herbal drug preparations', Council of Europe, Strasbourg, France, 2023. Zugriff am: 20.12.2024 [Online]. <https://www.edqm.eu/>
- [71] B. Baranyai, M. Krebs, C. Oehmke, and H. Joosten, 'Total biomass and annual yield of *Drosera* on cultivated Sphagnum in north-west Germany', *Mires and Peat*, vol. 28, no. 31, pp. 1–19, Oct. 2022, doi: 10.19189/MaP.2020.OMB.StA.1995.
- [72] M. Thum, 'Segregation of habitat and prey in two sympatric carnivorous plant species, *Drosera rotundifolia* and *Drosera intermedia*', *Oecologia*, vol. 70, no. 4, pp. 601–605, 1986, doi: 10.1007/BF00379912.
- [73] B. Steinhoff, 'Review: Quality of herbal medicinal products: State of the art of purity assessment', *Phytomedicine*, vol. 60, p. 153003, Jul. 2019, doi: 10.1016/j.phymed.2019.153003.
- [74] *DAB 6 - Ergänzungsbuch*. Deutscher Apotheker Verlag, 1989.
- [75] Ministerium für Gesundheit, *Deutsches Arzneibuch: DAB 7-DDR*, vol. 7. Ausgabe. Berlin: Akademie-Verlag, 1964, vol. vol. [1]. doi: 10.24355/DBBS.084-200510210200-738.
- [76] W. Hartke, R. Günther, J. Irmscher, H. Kreißig, and W. Seyfarth, Eds., *-AB-DDR 87-*. De Gruyter, 1987. doi: 10.1515/9783112622506.
- [77] *Österreichisches Arzneibuch*, 9. Wien: Österreichische Staatsdruckere, 1960.
- [78] Ministerium für öffentliche Gesundheit, *Pharmacopoea Belgica V*. Brüssel.
- [79] L. Krenn *et al.*, 'In vitro Antispasmodic and Antiinflammatory Effects of *Drosera rotundifolia*', *Arzneimittelforschung*, vol. 54, no. 07, pp. 402–405, Dec. 2011, doi: 10.1055/s-0031-1296991.

- [80] R. C. Montenegro *et al.*, 'Cytotoxic activity of naphthoquinones with special emphasis on juglone and its 5-O-methyl derivative', *Chemico-Biological Interactions*, vol. 184, no. 3, pp. 439–448, Mar. 2010, doi: 10.1016/j.cbi.2010.01.041.
- [81] M. R. S. Kumar, K. Aithal, B. N. Rao, N. Udupa, and B. S. S. Rao, 'Cytotoxic, genotoxic and oxidative stress induced by 1,4-naphthoquinone in B16F1 melanoma tumor cells', *Toxicology in Vitro*, vol. 23, no. 2, pp. 242–250, Mar. 2009, doi: 10.1016/j.tiv.2008.12.004.
- [82] P. Struchkov, V. Beloborodov, V. Kolkhir, I. Voskoboinikova, and A. Savvateev, 'Comparison of spectrophotometric methods of total flavonoid assay based on complex formation with aluminum chloride as applied to multicomponent herbal drug angionorm', *J Pharm Negative Results*, vol. 9, no. 1, p. 1, 2018, doi: 10.4103/jpnr.JPNR_22_17.
- [83] J.-L. Wolfender, 'HPLC in Natural Product Analysis: The Detection Issue', *Planta Med*, vol. 75, no. 07, pp. 719–734, Jun. 2009, doi: 10.1055/s-0028-1088393.
- [84] J. Wittig, I. Leipolz, E. Graefe, B. Jaki, D. Treutter, and M. Veit, 'Quantification of Procyanidins in Oral Herbal Medicinal Products Containing Extracts of Crataegus Species', *Arzneimittelforschung*, vol. 52, no. 02, pp. 89–96, Dec. 2011, doi: 10.1055/s-0031-1299862.
- [85] C. Møller, S. H. Hansen, and C. Cornett, 'Characterisation of tannin-containing herbal drugs by HPLC', *Phytochemical Analysis*, vol. 20, no. 3, pp. 231–239, May 2009, doi: 10.1002/pca.1119.
- [86] K. Wiberg, A. Hagman, S. P. Jacobsson, and P. Burén, 'Determination of the content and identity of lidocaine solutions with UV-visible spectroscopy and multivariate calibration', *Analyst*, vol. 126, no. 7, pp. 1142–1148, 2001, doi: 10.1039/b102545g.
- [87] Q. Xu, 'Advancing USP compendial methods for fixed dose combinations: A case study of metoprolol tartrate and hydrochlorothiazide tablets', *Journal of Pharmaceutical Analysis*, vol. 9, no. 2, pp. 77–82, Apr. 2019, doi: 10.1016/j.jpha.2018.12.003.
- [88] U. Holzgrabe, '11 The need for CE methods in pharmacopoeial monographs', in *Separation Science and Technology*, vol. 9, Elsevier, 2008, pp. 245–258. doi: 10.1016/S0149-6395(07)00011-6.
- [89] Deutscher Apotheker-Verlag Doktor Roland Schmiedel, Ed., *Europäisches Arzneibuch 11.4: Amtliche deutsche Ausgabe*, 11. Ausgabe, 4. Nachtrag. Stuttgart: Deutscher Apotheker Verlag, 2024.
- [90] F. Bracher, K. Hartke, and H. Böhme, Eds., *Arzneibuch-Kommentar: wissenschaftliche Erläuterungen zum Europäischen Arzneibuch und zum Deutschen Arzneibuch*. Stuttgart: Wiss. Verl.-Ges, 19.
- [91] PhytoLab, 'Consulting zur Erstellung einer Monographie für die Arzneidroge „Droserae herba“', Gutachten, Mar. 2024.
- [92] N. B. Ghate, A. Das, D. Chaudhuri, S. Panja, and N. Mandal, 'Sundew plant, a potential source of anti-inflammatory agents, selectively induces G2/M arrest and apoptosis in MCF-7 cells through upregulation of p53 and Bax/Bcl-2 ratio', *Cell Death Discov*, vol. 2, p. 15062, 2016, doi: 10.1038/cddiscovery.2015.62.
- [93] W. Makowski *et al.*, 'Effect of Agitation and Temporary Immersion on Growth and Synthesis of Antibacterial Phenolic Compounds in Genus Drosera', *Biomolecules*, vol. 14, no. 9, p. 1132, Sep. 2024, doi: 10.3390/biom14091132.
- [94] M. Schoenthaler *et al.*, 'Novel thiazolopyridine derivatives of diflapolin as dual sEH/FLAP inhibitors with improved solubility', *Bioorganic Chemistry*, vol. 139, p. 106685, Oct. 2023, doi: 10.1016/j.bioorg.2023.106685.
- [95] T. Teder *et al.*, 'Modulation of the 5-Lipoxygenase Pathway by Chalcogen-Containing Inhibitors of Leukotriene A4 Hydrolase', *IJMS*, vol. 24, no. 8, p. 7539, Apr. 2023, doi: 10.3390/ijms24087539.
- [96] O. Werz, E. Bürkert, B. Samuelsson, O. Rådmark, and D. Steinhilber, 'Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes', *Blood*, vol. 99, no. 3, pp. 1044–1052, Feb. 2002, doi: 10.1182/blood.V99.3.1044.
- [97] Y. B. Joshi and D. Pratică, 'The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype', *Front. Cell. Neurosci.*, vol. 8, Jan. 2015, doi: 10.3389/fncel.2014.00436.
- [98] T. S. Hallstrand and W. R. Henderson, 'An update on the role of leukotrienes in asthma', *Current Opinion in Allergy & Clinical Immunology*, vol. 10, no. 1, pp. 60–66, Feb. 2010, doi: 10.1097/ACI.0b013e32833489c3.

- [99] I. Serrano, C. Verdial, L. Tavares, and M. Oliveira, 'The Virtuous *Galleria mellonella* Model for Scientific Experimentation', *Antibiotics (Basel)*, vol. 12, no. 3, p. 505, Mar. 2023, doi: 10.3390/antibiotics12030505.
- [100] B. Pinto, A. C. Henriques, P. M. A. Silva, and H. Bousbaa, 'Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research', *Pharmaceutics*, vol. 12, no. 12, p. 1186, Dec. 2020, doi: 10.3390/pharmaceutics12121186.
- [101] A. T. Mbaveng and V. Kuete, 'Review of the chemistry and pharmacology of 7-Methyljuglone', *Afr Health Sci*, vol. 14, no. 1, pp. 201–205, Mar. 2014, doi: 10.4314/ahs.v14i1.31.
- [102] R. Gharbaran, C. Shi, O. Onwumere, and S. Redenti, 'Plumbagin Induces Cytotoxicity via Loss of Mitochondrial Membrane Potential and Caspase Activation in Metastatic Retinoblastoma', *Anticancer Res*, vol. 41, no. 10, pp. 4725–4732, Oct. 2021, doi: 10.21873/anticancer.15287.
- [103] C. Schwarz *et al.*, 'Respiratory Fungal Infections in Cystic Fibrosis: Diagnostic and Therapeutic Challenges', *Curr Fungal Infect Rep*, vol. 17, no. 3, pp. 202–213, Sep. 2023, doi: 10.1007/s12281-023-00467-z.
- [104] Y. Lee, N. Robbins, and L. E. Cowen, 'Molecular mechanisms governing antifungal drug resistance', *npj Antimicrob Resist*, vol. 1, no. 1, p. 5, Jul. 2023, doi: 10.1038/s44259-023-00007-2.
- [105] N. Zaidan, J. P. Hornak, and D. Reynoso, 'Extensively Drug-Resistant *Acinetobacter baumannii* Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination', *Antimicrob Agents Chemother*, vol. 65, no. 11, pp. e00924–21, Oct. 2021, doi: 10.1128/AAC.00924-21.
- [106] V. De Lastours *et al.*, 'Mortality in *Escherichia coli* bloodstream infections: antibiotic resistance still does not make it', *Journal of Antimicrobial Chemotherapy*, vol. 75, no. 8, pp. 2334–2343, Aug. 2020, doi: 10.1093/jac/dkaa161.
- [107] A. Driks, 'Overview: development in bacteria: spore formation in *Bacillus subtilis*', *Cellular and Molecular Life Sciences (CMLS)*, vol. 59, no. 3, pp. 389–391, Mar. 2002, doi: 10.1007/s00018-002-8430-x.
- [108] C. Fukushima *et al.*, 'Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone', *Annals of Allergy, Asthma & Immunology*, vol. 90, no. 6, pp. 646–651, Jun. 2003, doi: 10.1016/S1081-1206(10)61870-4.
- [109] M. Harmsen, L. Yang, S. J. Pamp, and T. Tolker-Nielsen, 'An update on *Pseudomonas aeruginosa* biofilm formation, tolerance, and dispersal', *FEMS Immunol Med Microbiol*, vol. 59, no. 3, pp. 253–268, Aug. 2010, doi: 10.1111/j.1574-695X.2010.00690.x.
- [110] C. A. Borges *et al.*, 'Multidrug-resistant pathogenic *Escherichia coli* isolated from wild birds in a veterinary hospital', *Avian Pathology*, vol. 46, no. 1, pp. 76–83, Jan. 2017, doi: 10.1080/03079457.2016.1209298.
- [111] E. Foster-Nyarko and M. J. Pallen, 'The microbial ecology of *Escherichia coli* in the vertebrate gut', *FEMS Microbiology Reviews*, vol. 46, no. 3, p. fuac008, May 2022, doi: 10.1093/femsre/fuac008.
- [112] J. B. Kaper, J. P. Nataro, and H. L. T. Mobley, 'Pathogenic *Escherichia coli*', *Nat Rev Microbiol*, vol. 2, no. 2, pp. 123–140, Feb. 2004, doi: 10.1038/nrmicro818.
- [113] A. Leimbach, J. Hacker, and U. Dobrindt, 'E. coli as an All-Rounder: The Thin Line Between Commensalism and Pathogenicity', in *Between Pathogenicity and Commensalism*, vol. 358, U. Dobrindt, J. H. Hacker, and C. Svanborg, Eds., in Current Topics in Microbiology and Immunology, vol. 358. , Berlin, Heidelberg: Springer Berlin Heidelberg, 2013, pp. 3–32. doi: 10.1007/82_2012_303.
- [114] G. Peirano and J. D. D. Pitout, 'Molecular epidemiology of *Escherichia coli* producing CTX-M β -lactamases: the worldwide emergence of clone ST131 O25:H4', *International Journal of Antimicrobial Agents*, vol. 35, no. 4, pp. 316–321, Apr. 2010, doi: 10.1016/j.ijantimicag.2009.11.003.
- [115] C. Ewers *et al.*, 'Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum- β -lactamase-producing *Escherichia coli* among companion animals', *Journal of Antimicrobial Chemotherapy*, vol. 65, no. 4, pp. 651–660, Apr. 2010, doi: 10.1093/jac/dkq004.
- [116] R. R. Nair, D. I. Andersson, and O. M. Warsi, 'Antibiotic resistance begets more resistance: chromosomal resistance mutations mitigate fitness costs conferred by multi-resistant clinical plasmids', *Microbiol Spectr*, vol. 12, no. 5, pp. e04206-23, May 2024, doi: 10.1128/spectrum.04206-23.

- [117] A. Hinz, A. Amado, R. Kassen, C. Bank, and A. Wong, 'Unpredictability of the Fitness Effects of Antimicrobial Resistance Mutations Across Environments in *Escherichia coli*', *Molecular Biology and Evolution*, vol. 41, no. 5, p. msae086, May 2024, doi: 10.1093/molbev/msae086.
- [118] N. L. Ben Zakour *et al.*, 'Sequential Acquisition of Virulence and Fluoroquinolone Resistance Has Shaped the Evolution of *Escherichia coli* ST131', *mBio*, vol. 7, no. 2, pp. e00347-16, May 2016, doi: 10.1128/mBio.00347-16.
- [119] S. A. Tursi and Ç. Tükel, 'Curli-Containing Enteric Biofilms Inside and Out: Matrix Composition, Immune Recognition, and Disease Implications', *Microbiol Mol Biol Rev*, vol. 82, no. 4, pp. e00028-18, Dec. 2018, doi: 10.1128/MMBR.00028-18.
- [120] D. O. Serra, A. M. Richter, and R. Hengge, 'Cellulose as an Architectural Element in Spatially Structured *Escherichia coli* Biofilms', *J Bacteriol*, vol. 195, no. 24, pp. 5540–5554, Dec. 2013, doi: 10.1128/JB.00946-13.
- [121] K. Schaufler *et al.*, 'Genomic and Functional Analysis of Emerging Virulent and Multidrug-Resistant *Escherichia coli* Lineage Sequence Type 648', *Antimicrob Agents Chemother*, vol. 63, no. 6, pp. e00243-19, Jun. 2019, doi: 10.1128/AAC.00243-19.
- [122] L. A. Salvador-Reyes and H. Luesch, 'Biological targets and mechanisms of action of natural products from marine cyanobacteria', *Nat Prod Rep*, vol. 32, no. 3, pp. 478–503, Mar. 2015, doi: 10.1039/c4np00104d.
- [123] D. N. Obot *et al.*, 'Advances in the molecular understanding of G protein-coupled receptors and their future therapeutic opportunities', *Futur J Pharm Sci*, vol. 7, no. 1, p. 194, Dec. 2021, doi: 10.1186/s43094-021-00341-0.
- [124] M. Sandy and A. Butler, 'Microbial Iron Acquisition: Marine and Terrestrial Siderophores', *Chem. Rev.*, vol. 109, no. 10, pp. 4580–4595, Oct. 2009, doi: 10.1021/cr9002787.
- [125] S. C. Andrews, A. K. Robinson, and F. Rodríguez-Quñones, 'Bacterial iron homeostasis', *FEMS Microbiol Rev*, vol. 27, no. 2–3, pp. 215–237, Jun. 2003, doi: 10.1016/S0168-6445(03)00055-X.
- [126] D. Y. Mason and C. R. Taylor, 'Distribution of transferrin, ferritin, and lactoferrin in human tissues.', *J Clin Pathol*, vol. 31, no. 4, pp. 316–327, Apr. 1978, doi: 10.1136/jcp.31.4.316.
- [127] C. M. Gehrer *et al.*, 'Availability of Ferritin-Bound Iron to Enterobacteriaceae', *IJMS*, vol. 23, no. 21, p. 13087, Oct. 2022, doi: 10.3390/ijms232113087.
- [128] E. Nemeth and T. Ganz, 'Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis', *IJMS*, vol. 22, no. 12, p. 6493, Jun. 2021, doi: 10.3390/ijms22126493.
- [129] Z. Zou, J. I. Robinson, L. K. Steinberg, and J. P. Henderson, 'Uropathogenic *Escherichia coli* wield enterobactin-derived catabolites as siderophores', *Journal of Biological Chemistry*, vol. 300, no. 1, p. 105554, Jan. 2024, doi: 10.1016/j.jbc.2023.105554.
- [130] J. Ren, S. Meng, Ch. E. Lekka, and E. Kaxiras, 'Complexation of Flavonoids with Iron: Structure and Optical Signatures', *J. Phys. Chem. B*, vol. 112, no. 6, pp. 1845–1850, Feb. 2008, doi: 10.1021/jp076881e.
- [131] Z. Kejík *et al.*, 'Iron Complexes of Flavonoids-Antioxidant Capacity and Beyond', *IJMS*, vol. 22, no. 2, p. 646, Jan. 2021, doi: 10.3390/ijms22020646.
- [132] V. Hancock, M. Dahl, and P. Klemm, 'Abolition of Biofilm Formation in Urinary Tract *Escherichia coli* and *Klebsiella* Isolates by Metal Interference through Competition for Fur', *Appl Environ Microbiol*, vol. 76, no. 12, pp. 3836–3841, Jun. 2010, doi: 10.1128/AEM.00241-10.
- [133] Y. Wu and F. W. Outten, 'IscR Controls Iron-Dependent Biofilm Formation in *Escherichia coli* by Regulating Type I Fimbria Expression', *J Bacteriol*, vol. 191, no. 4, pp. 1248–1257, Feb. 2009, doi: 10.1128/JB.01086-08.
- [134] C. Wang, D. Yang, Y. Wang, and W. Ni, 'Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence', *Front. Pharmacol.*, vol. 13, p. 896971, Apr. 2022, doi: 10.3389/fphar.2022.896971.
- [135] S. Ong'uti, M. Czech, E. Robilotti, and M. Holubar, 'Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria', *Clinical Infectious Diseases*, vol. 74, no. 7, pp. 1303–1312, Apr. 2022, doi: 10.1093/cid/ciab757.
- [136] P. J. Simner and R. Patel, 'Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?', *J Clin Microbiol*, vol. 59, no. 1, pp. e00951-20, Dec. 2020, doi: 10.1128/JCM.00951-20.
- [137] C. Majdi, V. Duvauchelle, P. Meffre, and Z. Benfodda, 'An overview on the antibacterial properties of juglone, naphthazarin, plumbagin and lawsone derivatives and their metal

- complexes', *Biomedicine & Pharmacotherapy*, vol. 162, p. 114690, Jun. 2023, doi: 10.1016/j.biopha.2023.114690.
- [138] R. Song *et al.*, 'Naphthoquinone-derivative as a synthetic compound to overcome the antibiotic resistance of methicillin-resistant *S. aureus*', *Commun Biol*, vol. 3, no. 1, p. 529, Sep. 2020, doi: 10.1038/s42003-020-01261-0.
- [139] N. Mone *et al.*, 'Naphthoquinones and Their Derivatives: Emerging Trends in Combating Microbial Pathogens', *Coatings*, vol. 11, no. 4, p. 434, Apr. 2021, doi: 10.3390/coatings11040434.
- [140] P. Ravichandiran, S. Sheet, D. Premnath, A. R. Kim, and D. J. Yoo, '1,4-Naphthoquinone Analogues: Potent Antibacterial Agents and Mode of Action Evaluation', *Molecules*, vol. 24, no. 7, p. 1437, Apr. 2019, doi: 10.3390/molecules24071437.
- [141] A. Sen, Y. Zhou, and J. A. Imlay, 'During Oxidative Stress the Clp Proteins of *Escherichia coli* Ensure that Iron Pools Remain Sufficient To Reactivate Oxidized Metalloenzymes', *J Bacteriol*, vol. 202, no. 18, pp. e00235-20, Aug. 2020, doi: 10.1128/JB.00235-20.
- [142] V. Braun and M. Braun, 'Iron transport and signaling in *Escherichia coli*', *FEBS Letters*, vol. 529, no. 1, pp. 78–85, Oct. 2002, doi: 10.1016/S0014-5793(02)03185-X.
- [143] F. Jiang, X. Huang, N. L. Barbieri, C. M. Logue, L. K. Nolan, and G. Li, 'Citrate utilization under anaerobic environment in *ESCHERICHIA COLI* is under direct control of Fnr and indirect control of ARCA and Fnr via CITA-CITB system', *Environmental Microbiology*, vol. 23, no. 3, pp. 1496–1509, Mar. 2021, doi: 10.1111/1462-2920.15357.
- [144] K. M. Pos, P. Dimroth, and M. Bott, 'The *Escherichia coli* Citrate Carrier CitT: a Member of a Novel Eubacterial Transporter Family Related to the 2-Oxoglutarate/Malate Translocator from Spinach Chloroplasts', *J Bacteriol*, vol. 180, no. 16, pp. 4160–4165, Aug. 1998, doi: 10.1128/JB.180.16.4160-4165.1998.
- [145] R. Guo, X. Luo, J. Liu, and H. Lu, 'Mass spectrometry based targeted metabolomics precisely characterized new functional metabolites that regulate biofilm formation in *Escherichia coli*', *Analytica Chimica Acta*, vol. 1145, pp. 26–36, Feb. 2021, doi: 10.1016/j.aca.2020.12.021.
- [146] M.-L. Hirsch and G. N. Cohen, 'Amino-acid utilization in bacterial growth. 1. Peptide utilization by a leucine-requiring mutant of *Escherichia coli*', *Biochemical Journal*, vol. 53, no. 1, pp. 25–30, Jan. 1953, doi: 10.1042/bj0530025.
- [147] J. E. Lee, K. A. Cornell, M. K. Riscoe, and P. L. Howell, 'Structure of *E. coli* 5'-methylthioadenosine/S-adenosylhomocysteine Nucleosidase Reveals Similarity to the Purine Nucleoside Phosphorylases', *Structure*, vol. 9, no. 10, pp. 941–953, Oct. 2001, doi: 10.1016/S0969-2126(01)00656-6.
- [148] K. Igarashi and K. Kashiwagi, 'Effects of polyamines on protein synthesis and growth of *Escherichia coli*', *J Biol Chem*, vol. 293, no. 48, pp. 18702–18709, Nov. 2018, doi: 10.1074/jbc.TM118.003465.
- [149] A. L. Dela Vega and A. H. Delcour, 'Polyamines decrease *Escherichia coli* outer membrane permeability', *J Bacteriol*, vol. 178, no. 13, pp. 3715–3721, Jul. 1996, doi: 10.1128/jb.178.13.3715-3721.1996.
- [150] L. Miller-Fleming, V. Olin-Sandoval, K. Campbell, and M. Ralser, 'Remaining Mysteries of Molecular Biology: The Role of Polyamines in the Cell', *Journal of Molecular Biology*, vol. 427, no. 21, pp. 3389–3406, Oct. 2015, doi: 10.1016/j.jmb.2015.06.020.
- [151] K. Thongbhubate, Y. Nakafuji, R. Matsuoka, S. Kakegawa, and H. Suzuki, 'Effect of Spermidine on Biofilm Formation in *Escherichia coli* K-12', *J Bacteriol*, vol. 203, no. 10, Apr. 2021, doi: 10.1128/JB.00652-20.
- [152] K. Thongbhubate, Y. Nakafuji, R. Matsuoka, S. Kakegawa, and H. Suzuki, 'Effect of Spermidine on Biofilm Formation in *Escherichia coli* K-12', *J Bacteriol*, vol. 203, no. 10, pp. e00652-20, Apr. 2021, doi: 10.1128/JB.00652-20.
- [153] X. Zhang, Y. Zhang, J. Liu, and H. Liu, 'PotD protein stimulates biofilm formation by *Escherichia coli*', *Biotechnol Lett*, vol. 35, no. 7, pp. 1099–1106, Jul. 2013, doi: 10.1007/s10529-013-1184-8.
- [154] Z. Qiao *et al.*, 'Structural insights into polyamine spermidine uptake by the ABC transporter PotD-PotABC', *Sci. Adv.*, vol. 10, no. 38, p. eado8107, Sep. 2024, doi: 10.1126/sciadv.ado8107.
- [155] M. Blum *et al.*, 'InterPro: the protein sequence classification resource in 2025', *Nucleic Acids Research*, vol. 53, no. D1, pp. D444–D456, Jan. 2025, doi: 10.1093/nar/gkae1082.

- [156] W. R. Pearson, 'An Introduction to Sequence Similarity ("Homology") Searching', *CP in Bioinformatics*, vol. 42, no. 1, Jun. 2013, doi: 10.1002/0471250953.bi0301s42.
- [157] *Bioinformatics for Beginners*. Elsevier, 2014. doi: 10.1016/C2012-0-07153-0.
- [158] 'Conserved Domains and Protein Classification Help'. Zugriff am: 16.04.2025 [Online]. https://www.ncbi.nlm.nih.gov/Structure/cdd/cdd_help.shtml#WRPSBExpect
- [159] Y. Tabana, D. Babu, R. Fahlman, A. G. Siraki, and K. Barakat, 'Target identification of small molecules: an overview of the current applications in drug discovery', *BMC Biotechnol*, vol. 23, no. 1, p. 44, Oct. 2023, doi: 10.1186/s12896-023-00815-4.
- [160] J. Hidalgo *et al.*, '720. Efficacy of Nifurtimox + Eflornithine in the Treatment of African Trypanosomiasis. Systematic Review', *Open Forum Infectious Diseases*, vol. 8, no. Supplement_1, pp. S459–S459, Dec. 2021, doi: 10.1093/ofid/ofab466.917.
- [161] R. R. Somani, P. R. Rai, and P. S. Kandpile, 'Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases', *MPMC*, vol. 18, no. 12, pp. 1008–1021, Jun. 2018, doi: 10.2174/1389557517666170927130526.
- [162] M. D. Temple, G. G. Perrone, and I. W. Dawes, 'Complex cellular responses to reactive oxygen species', *Trends in Cell Biology*, vol. 15, no. 6, pp. 319–326, Jun. 2005, doi: 10.1016/j.tcb.2005.04.003.
- [163] K. Ejrnæs *et al.*, 'Characteristics of *Escherichia coli* causing persistence or relapse of urinary tract infections: Phylogenetic groups, virulence factors and biofilm formation', *Virulence*, vol. 2, no. 6, pp. 528–537, Nov. 2011, doi: 10.4161/viru.2.6.18189.
- [164] Z. Naziri, J. A. Kilegolan, M. S. Moezzi, and A. Derakhshandeh, 'Biofilm formation by uropathogenic *Escherichia coli*: a complicating factor for treatment and recurrence of urinary tract infections', *Journal of Hospital Infection*, vol. 117, pp. 9–16, Nov. 2021, doi: 10.1016/j.jhin.2021.08.017.
- [165] Z. Naziri, J. A. Kilegolan, M. S. Moezzi, and A. Derakhshandeh, 'Biofilm formation by uropathogenic *Escherichia coli*: a complicating factor for treatment and recurrence of urinary tract infections', *Journal of Hospital Infection*, vol. 117, pp. 9–16, Nov. 2021, doi: 10.1016/j.jhin.2021.08.017.
- [166] G. C. Schito *et al.*, 'The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections', *International Journal of Antimicrobial Agents*, vol. 34, no. 5, pp. 407–413, Nov. 2009, doi: 10.1016/j.ijantimicag.2009.04.012.
- [167] N. Høiby, T. Bjarnsholt, M. Givskov, S. Molin, and O. Ciofu, 'Antibiotic resistance of bacterial biofilms', *International Journal of Antimicrobial Agents*, vol. 35, no. 4, pp. 322–332, Apr. 2010, doi: 10.1016/j.ijantimicag.2009.12.011.
- [168] J. Marcon, S. Schubert, C. G. Stief, and G. Magistro, 'In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections', *Infection*, vol. 47, no. 6, pp. 937–944, Dec. 2019, doi: 10.1007/s15010-019-01315-4.
- [169] Statista, 'Top 10 der umsatzstärksten Indikationsgruppen von Phytopharmaka'. Zugriff am: 20.12.2024 [Online]. <https://de.statista.com/statistik/daten/studie/526054/umfrage/top-10-der-umsatzstaerksten-indikationsgruppen-von-phytopharmaka/>
- [170] K. Gupta, M. Y. Chou, A. Howell, C. Wobbe, R. Grady, and A. E. Stapleton, 'Cranberry Products Inhibit Adherence of P-Fimbriated *Escherichia coli* to Primary Cultured Bladder and Vaginal Epithelial Cells', *Journal of Urology*, vol. 177, no. 6, pp. 2357–2360, Jun. 2007, doi: 10.1016/j.juro.2007.01.114.
- [171] Y. Liu, A. M. Gallardo-Moreno, P. A. Pinzon-Arango, Y. Reynolds, G. Rodriguez, and T. A. Camesano, 'Cranberry changes the physicochemical surface properties of *E. coli* and adhesion with uroepithelial cells', *Colloids and Surfaces B: Biointerfaces*, vol. 65, no. 1, pp. 35–42, Aug. 2008, doi: 10.1016/j.colsurfb.2008.02.012.
- [172] N. Rafsanjany, J. Senker, S. Brandt, U. Dobrindt, and A. Hensel, 'In Vivo Consumption of Cranberry Exerts ex Vivo Antiadhesive Activity against *FimH* -Dominated Uropathogenic *Escherichia coli*: A Combined in Vivo, ex Vivo, and in Vitro Study of an Extract from *Vaccinium macrocarpon*', *J. Agric. Food Chem.*, vol. 63, no. 40, pp. 8804–8818, Oct. 2015, doi: 10.1021/acs.jafc.5b03030.
- [173] C. Roussel *et al.*, 'UPEC Colonic-Virulence and Urovirulence Are Blunted by Proanthocyanidins-Rich Cranberry Extract Microbial Metabolites in a Gut Model and a 3D

- Tissue-Engineered Urothelium', *Microbiol Spectr*, vol. 10, no. 5, pp. e02432-21, Oct. 2022, doi: 10.1128/spectrum.02432-21.
- [174] G. Schindler *et al.*, 'Urinary Excretion and Metabolism of Arbutin after Oral Administration of *Arctostaphylos uvae ursi* Extract as Film-Coated Tablets and Aqueous Solution in Healthy Humans', *The Journal of Clinical Pharma*, vol. 42, no. 8, pp. 920–927, Aug. 2002, doi: 10.1177/009127002401102740.
- [175] K. Afshar *et al.*, 'Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) – a double-blind, randomized, controlled comparative effectiveness trial', *BMC Complement Altern Med*, vol. 18, no. 1, p. 203, Dec. 2018, doi: 10.1186/s12906-018-2266-x.
- [176] M. Zare, M. J. G. T. Vehreschild, and F. Wagenlehner, 'Management of uncomplicated recurrent urinary tract infections', *BJU International*, vol. 129, no. 6, pp. 668–678, Jun. 2022, doi: 10.1111/bju.15630.
- [177] B. Foxman, 'Recurring urinary tract infection: incidence and risk factors.', *Am J Public Health*, vol. 80, no. 3, pp. 331–333, Mar. 1990, doi: 10.2105/AJPH.80.3.331.
- [178] R. Ikahelmo *et al.*, 'Recurrence of Urinary Tract Infection in a Primary Care Setting: Analysis of a I-Year Follow-up of 179 Women', *Clinical Infectious Diseases*, vol. 22, no. 1, pp. 91–99, Jan. 1996, doi: 10.1093/clinids/22.1.91.
- [179] A. Ghosh, N. Jayaraman, and D. Chatterji, 'Small-Molecule Inhibition of Bacterial Biofilm', *ACS Omega*, vol. 5, no. 7, pp. 3108–3115, Feb. 2020, doi: 10.1021/acsomega.9b03695.
- [180] A. Crozier, D. Del Rio, and M. N. Clifford, 'Bioavailability of dietary flavonoids and phenolic compounds', *Molecular Aspects of Medicine*, vol. 31, no. 6, pp. 446–467, Dec. 2010, doi: 10.1016/j.mam.2010.09.007.
- [181] L. Zhang, Z. Zuo, and G. Lin, 'Intestinal and Hepatic Glucuronidation of Flavonoids', *Mol. Pharmaceutics*, vol. 4, no. 6, pp. 833–845, Dec. 2007, doi: 10.1021/mp700077z.
- [182] N. Thakor and B. Janathia, 'Plumbagin: A Potential Candidate for Future Research and Development', *CPB*, vol. 23, no. 15, pp. 1800–1812, Dec. 2022, doi: 10.2174/1389201023666211230113146.
- [183] Y. Hsieh, L. Lin, and T. Tsai, 'Measurement and pharmacokinetic study of plumbagin in a conscious freely moving rat using liquid chromatography/tandem mass spectrometry', *Journal of Chromatography B*, vol. 844, no. 1, pp. 1–5, Nov. 2006, doi: 10.1016/j.jchromb.2006.06.024.
- [184] B. Chandrasekaran and B. Nagarajan, 'Metabolism of echitamine and plumbagin in rats', *J Biosci*, vol. 3, no. 4, pp. 395–400, Dec. 1981, doi: 10.1007/BF02702627.
- [185] P. C. Ho, D. J. Saville, and S. Wanwimolruk, 'Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds', *J Pharm Pharm Sci*, vol. 4, no. 3, pp. 217–227, 2001.
- [186] A. Chen, X. Zhou, S. Tang, M. Liu, and X. Wang, 'Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach', *Sci Rep*, vol. 6, no. 1, p. 28482, Jun. 2016, doi: 10.1038/srep28482.
- [187] F. R. Bortolozo, T. R. Aguiar, F. A. Hansel, E. F. Rosa Filho, L. V. Parron, and S. Froehner, 'Peatland as a natural sink for pesticides from no-till systems in subtropical climate', *Agricultural Water Management*, vol. 163, pp. 19–27, Jan. 2016, doi: 10.1016/j.agwat.2015.08.028.
- [188] K. F. M. Opuni *et al.*, 'Contamination of herbal medicinal products in low-and-middle-income countries: A systematic review', *Heliyon*, vol. 9, no. 9, p. e19370, Sep. 2023, doi: 10.1016/j.heliyon.2023.e19370.
- [189] B. Baranyai, M. Krebs, C. Oehmke, and H. Joosten, 'Seed germination and seedling survival of *Drosera rotundifolia* (L.) cultivated on Sphagnum: Influence of cultivation methods and conditions, seed density, Sphagnum species and vascular plant cover', *Mires Peat*, vol. 27, no. 15, pp. 1–14, May 2021, doi: 10.19189/MaP.2020.APG.StA.1937.
- [190] J. C. Stevens Barrón, C. Chapa González, E. Álvarez Parrilla, and L. A. De la Rosa, 'Nanoparticle-Mediated Delivery of Flavonoids: Impact on Proinflammatory Cytokine Production: A Systematic Review', *Biomolecules*, vol. 13, no. 7, p. 1158, Jul. 2023, doi: 10.3390/biom13071158.